These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 24067486)
1. Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse. Chimenti MS; Esposito M; Giunta A; Graceffa D; Babino G; Teoli M; Mazzotta A; Pericone R; Chimenti S Int J Immunopathol Pharmacol; 2013; 26(3):833-8. PubMed ID: 24067486 [TBL] [Abstract][Full Text] [Related]
2. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan. Chastek B; Fox KM; Watson C; Gandra SR Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239 [TBL] [Abstract][Full Text] [Related]
3. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs. Perrotta FM; Marchesoni A; Lubrano E J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925 [TBL] [Abstract][Full Text] [Related]
4. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. de Vlam K; Lories RJ Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275 [TBL] [Abstract][Full Text] [Related]
5. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. De Felice C; Mazzotta A; Esposito M; Bianchi L; Chimenti S J Dermatolog Treat; 2006; 17(6):355-8. PubMed ID: 17853309 [TBL] [Abstract][Full Text] [Related]
6. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650 [TBL] [Abstract][Full Text] [Related]
7. Application of composite disease activity scores in psoriatic arthritis to the PRESTA data set. FitzGerald O; Helliwell P; Mease P; Mumtaz A; Coates L; Pedersen R; Nab H; Molta C Ann Rheum Dis; 2012 Mar; 71(3):358-62. PubMed ID: 21989542 [TBL] [Abstract][Full Text] [Related]
8. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy. Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950 [TBL] [Abstract][Full Text] [Related]
9. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Yamauchi PS; Gindi V; Lowe NJ Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340 [TBL] [Abstract][Full Text] [Related]
11. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept. Lubrano E; Spadaro A; Marchesoni A; Olivieri I; Scarpa R; D'Angelo S; Salvarani C; Mathieu A; Cauli A; Ferrara N; Helliwell P Clin Exp Rheumatol; 2011; 29(1):80-4. PubMed ID: 21345296 [TBL] [Abstract][Full Text] [Related]
14. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients. Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492 [TBL] [Abstract][Full Text] [Related]
15. A case of tuberculosis in a patient on Efalizumab and Etanercept for treatment of refractory palmopustular psoriasis and psoriatic arthritis. Kitamura G; Mehr N; Anderson N; Sirichotiratana M Dermatol Online J; 2009 Feb; 15(2):11. PubMed ID: 19336028 [TBL] [Abstract][Full Text] [Related]
16. Is reduction or discontinuation of therapy an acceptable possibility in psoriatic arthritis? Mease P Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S59-62. PubMed ID: 24129140 [TBL] [Abstract][Full Text] [Related]
17. [Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis]. Wozel G Hautarzt; 2005 Sep; 56(9):819-30. PubMed ID: 16133634 [TBL] [Abstract][Full Text] [Related]
18. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064 [TBL] [Abstract][Full Text] [Related]
19. Synovial biomarkers in psoriatic arthritis. Fiocco U; Oliviero F; Sfriso P; Calabrese F; Lunardi F; Scagliori E; Rubaltelli L; Stramare R; Di Maggio A; Nardacchione R; Cozzi L; Molena B; Felicetti M; Gazzola K; Lo Nigro A; Accordi B; Roux-Lombard P; Dayer JM; Punzi L J Rheumatol Suppl; 2012 Jul; 89():61-4. PubMed ID: 22751595 [TBL] [Abstract][Full Text] [Related]
20. Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Iannone F; Lopriore S; Bucci R; Scioscia C; Anelli MG; Notarnicola A; Lapadula G Scand J Rheumatol; 2015 May; 44(3):192-9. PubMed ID: 25564882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]